Evidence map›Paper›PMID 26073770›Full record

Trial reportTrials2015

Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial.

Anke Heida, Alie Dijkstra, Henk Groen, Anneke Muller Kobold, Henkjan Verkade, Patrick van Rheenen

Open access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
7.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Remote care through telehealth for people with inflammatory bowel disease.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anke HeidaDepartment of Pediatric Gastroenterology, University of Groningen, University Medical Centre Groningen, PO Box 30001, 9700, RB, Groningen, The Netherlands. a.heida01@umcg.nl.
Alie DijkstraDepartment of Pediatric Gastroenterology, University of Groningen, University Medical Centre Groningen, PO Box 30001, 9700, RB, Groningen, The Netherlands. a.dijkstra03@umcg.nl.
Henk GroenDepartment of Clinical Epidemiology (Medical Technology Assessment), University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands. h.groen01@umcg.nl.
Anneke Muller KoboldDepartment of Laboratory Medicine, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands. a.c.muller@umcg.nl.
Henkjan VerkadeDepartment of Pediatric Gastroenterology, University of Groningen, University Medical Centre Groningen, PO Box 30001, 9700, RB, Groningen, The Netherlands. h.j.verkade@umcg.nl.
Patrick van RheenenDepartment of Pediatric Gastroenterology, University of Groningen, University Medical Centre Groningen, PO Box 30001, 9700, RB, Groningen, The Netherlands. p.f.van.rheenen@umcg.nl.
University Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo prevent clinical relapse in teenagers with inflammatory bowel disease (IBD) there is a need to monitor disease activity continuously. Timely optimisation of medical treatment may nip a preclinical relapse in the bud and change the natural course of IBD. Traditionally, disease monitoring is done during scheduled visits, but this is when most teenagers report full control. IBD care could be more efficient if patients were seen at times of clinical need. This study aims to examine the effectiveness of a web-assisted calprotectin-based treatment algorithm (IBD-live) compared with usual practices in teenagers with IBD. METHODS/

designA randomized trial of web-based disease monitoring versus usual care is conducted at 10 Dutch IBD care centers. We plan to recruit 180 patients between 10- and 19-years old with quiescent IBD at baseline. Teenagers assigned to IBD-live will use the flarometer--an automatic cumulation of disease activity and fecal calprotectin measurements- to estimate probability of relapse. In case the flarometer indicates high risk the patient requires treatment intensification in accordance with national guidelines; low risk means that maintenance therapy is unchanged; and intermediate risk requires optimisation of drug adherence. Patients assigned to usual practice get the best accepted medical care with regular health checks. Primary outcome is the frequency of relapse at 52 weeks of follow-up. The diagnosis of relapse is based on a clinical activity index score >10 points necessitating remission induction therapy. Secondary outcomes include quality of life and cost-effectiveness. DISCUSSION: Web-assisted monitoring of disease activity with rapid access for those with acute relapse may allow teenagers to develop skills that are required of adult patients (including communication and self-determination). Similar monitoring systems have been introduced for teenagers with asthma and diabetes, with a positive effect on disease control, but the intervention has not been evaluated in teenagers with IBD. A randomized trial in adult patients with ulcerative colitis showed that a web-assisted treatment algorithm is feasible, safe and cost-effective. Results of the current trial are expected to have important implications for teenagers with IBD that incurs substantial health burdens and economic costs.

trial registrationDutch Trial Register identifier: NTR3759 (registered 29 December 2012).

Indexed as

Clinical ProtocolsAdolescentAdultAlgorithmsChildData Interpretation, StatisticalHumansInflammatory Bowel DiseasesLeukocyte L1 Antigen ComplexOutcome Assessment, Health CareSample SizeTelemedicineLeukocyte L1 Antigen Complex

Identifiers

PMID26073770
PMCPMC4486429
OpenAlexW2119172013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.